Shui C, Khan W B, Leigh B R, Turner A M, Wilder R B, Knox S J
Department of Radiation Oncology, Stanford University Hospital, California 94305, USA.
Cancer Res. 1995 Aug 1;55(15):3431-7.
Recombinant human stem cell factor (SCF) binds to the c-kit receptor on human bone marrow progenitor cells and enhances their survival following irradiation. Since the c-kit receptor has also been detected on malignant cells, experiments were performed to study the effect of SCF on the proliferation and radiation survival of a variety of both c-kit-positive and -negative human tumor cell lines using [3H]thymidine incorporation and colony formation assays. The addition of SCF to both c-kit-positive and -negative cell line cultures had no significant effect on the stimulation index (in [3H]thymidine assay). In contrast, colony formation by H69 (small cell lung cancer cell line), H128 (small cell lung cancer cell line), and HEL (erythroid leukemia cell line) cells was enhanced by SCF in a dose-dependent manner, but SCF did not promote the in vivo growth of H128 xenograft tumors in terms of graft rate, time from implantation to tumor detection, or tumor size. Furthermore, SCF did not significantly increase the surviving fraction of either c-kit-positive or -negative cell lines following radiation, and there were no statistically significant differences between D0 [defined by the slope of the terminal exponential region of the two-component (single-hit multitarget model) survival curve where slope = 1/D0], Dq (quasithreshold dose), n (extrapolation number), alpha, and beta values for any of the cell lines studied that were irradiated with and without SCF. Finally, nude mice with transplanted human LG425 cutaneous T-cell lymphoma (c-kit positive) were treated with 10 Gy with or without SCF (100 micrograms/kg i.p. 20 h before, 2 h before, and 4 h after irradiation). There were no significant differences in the median tumor quadrupling time between groups that received either no treatment or SCF alone, or between groups treated with 10 Gy and SCF or 10 Gy alone (P > 0.05). These results are encouraging and suggest that SCF does not stimulate tumor cell proliferation in vivo or enhance the survival of tumor cells following irradiation.
重组人干细胞因子(SCF)与人类骨髓祖细胞上的c-kit受体结合,并在照射后提高其存活率。由于在恶性细胞上也检测到了c-kit受体,因此进行了实验,使用[3H]胸腺嘧啶核苷掺入法和集落形成试验,研究SCF对多种c-kit阳性和阴性人类肿瘤细胞系增殖和辐射存活的影响。在c-kit阳性和阴性细胞系培养物中添加SCF对刺激指数(在[3H]胸腺嘧啶核苷试验中)没有显著影响。相比之下,SCF以剂量依赖的方式增强了H69(小细胞肺癌细胞系)、H128(小细胞肺癌细胞系)和HEL(红白血病细胞系)细胞的集落形成,但就移植率、从植入到检测到肿瘤的时间或肿瘤大小而言,SCF并未促进H128异种移植肿瘤的体内生长。此外,SCF在辐射后并未显著增加c-kit阳性或阴性细胞系的存活分数,并且对于任何研究的接受或未接受SCF照射的细胞系,其D0[由双组分(单靶多击模型)存活曲线的终末指数区域的斜率定义,其中斜率=1/D0]、Dq(准阈值剂量)、n(外推数)、α和β值之间没有统计学上的显著差异。最后,对移植了人类LG425皮肤T细胞淋巴瘤(c-kit阳性)的裸鼠进行10 Gy照射,照射前20小时、照射前2小时和照射后4小时腹腔注射100微克/千克SCF或不注射。未接受任何治疗或仅接受SCF治疗的组之间,以及接受10 Gy和SCF治疗或仅接受10 Gy治疗的组之间,肿瘤四倍体时间中位数没有显著差异(P>0.05)。这些结果令人鼓舞,表明SCF在体内不会刺激肿瘤细胞增殖,也不会增强照射后肿瘤细胞的存活。